Wara Samar
16th June 2025
Atraverse Medical Secures $29.4M to Accelerate Growth of HOTWIRE™ and Advance Left-Heart Access Innovation
Atraverse Medical, a company developing next-generation technologies for transseptal access, has closed a $29.4 million follow-on financing round to propel the commercialization of its flagship product, HOTWIRE™. The funding brings the company’s total capital raised to over $40 million, building on a previous $12.5 million seed round that helped secure FDA 510(k) clearance and launch early U.S. commercialization efforts.
HOTWIRE™: Setting a New Standard in Left-Heart Access
At the heart of Atraverse’s efforts is HOTWIRE™, a novel radiofrequency (RF) guidewire designed to streamline left-heart access through a zero-exchange workflow and universal sheath compatibility. Engineered for enhanced echogenicity and rail stiffness, HOTWIRE™ is already demonstrating strong clinical momentum, approaching 1,000 successful procedures across 10 different introducer sheaths.
“This successful financing reinforces the market need for continued innovation in the left-heart access arena and is a testament to the exceptional vision of our founders and inventors: Eric Sauter, COO, Dr. Steven Mickelsen, CTSO, and Jay Kelley, CMO,” said John Slump, CEO/President and Co-Founder of Atraverse Medical. “This funding catapults us to our next chapter—expanding access to our technology, growing our talented team, and accelerating the pipeline of innovations that will continue to shape the future of electrophysiology and transseptal access. We’re thrilled to see such strong support from investors who recognize the significant potential for HOTWIRE™ to set a new standard as the future of left-heart access.”
Industry Backing and Clinical Adoption
Investors include a mix of MedTech entrepreneurs, family offices, and angel investors, all aligned in their belief that HOTWIRE™ represents a transformative leap in transseptal access technology.
“The most transformative medical technologies don’t just improve procedures—they reimagine entire categories,” said Jean-Luc Pageard, a seasoned innovator and investor in electrophysiology, in a statement. “HOTWIRE™ is redefining how physicians approach left-heart access. I invested in Atraverse because the company is developing a scalable, category-shaping innovation that is likely to become the new standard of care.”
The enthusiasm is echoed in clinical settings. Dr. Vivek Y. Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, commented, “HOTWIRE™ delivers clinically significant advantages over existing left-heart access devices, and we are excited to be an early adopter and commercial customer.”
Also Read: Cohort Announced: MedTech Innovator’s 2025 Startups to Present at MedTech World Bay Area, June 26–27
A Track Record of Innovation
Atraverse was founded in 2022 by the team behind FARAPULSE, which was acquired in 2021. With HOTWIRE™, the company continues its mission to deliver practical, impactful tools for physicians treating cardiovascular disease. The current funding will support expanded manufacturing, new product development, and continued clinical rollout in the U.S.
Up Next: MedTech World Bay Area, California
Be part of MedTech World Bay Area, California, on June 26–27, 2025 — a curated two-day event bringing together sponsors, investors, and top-tier MedTech startups. Held in collaboration with MedTech Innovator, this exclusive experience offers direct access to over 100 emerging companies and influential leaders shaping the next wave of healthcare innovation. Whether you’re exploring new partnerships or aiming to stay at the forefront of MedTech, this is where meaningful connections take root. Interested in sponsoring or attending? Reach out to [email protected].
